HRP20040552A2 - Process for the preparation of crystalline imipenem - Google Patents

Process for the preparation of crystalline imipenem Download PDF

Info

Publication number
HRP20040552A2
HRP20040552A2 HR20040552A HRP20040552A HRP20040552A2 HR P20040552 A2 HRP20040552 A2 HR P20040552A2 HR 20040552 A HR20040552 A HR 20040552A HR P20040552 A HRP20040552 A HR P20040552A HR P20040552 A2 HRP20040552 A2 HR P20040552A2
Authority
HR
Croatia
Prior art keywords
imipenem
water
treatment
solution
crystalline
Prior art date
Application number
HR20040552A
Other languages
Croatian (hr)
Inventor
Bishwa Prakash Rai
Neera Tewari
Yatendra Kumar
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of HRP20040552A2 publication Critical patent/HRP20040552A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

Područje izuma Field of invention

Ovaj se izum odnosi na industrijski povoljan postupak, prihvatljive cijene, za pripremu imipenema visoke čistoće. This invention relates to an industrially advantageous, cost-effective process for the preparation of high purity imipenem.

Pozadina izuma Background of the invention

Imipenem monohidrat je N-formimidoilni derivat tienamicina strukturne formule I: Imipenem monohydrate is an N-formimidoyl derivative of thienamycin of structural formula I:

[image] [image]

To je prvi klinički dostupan član nove grupe β-laktamskih antibiotika koji posjeduju karbapenemski prstenasti sustav. Imipenem pokazuje izuzetno širok spektar aktivnosti protiv gram-pozitivnih i gram-negativnih aerobnih i anaerobnih vrsta, djelomično i zbog svoje velike stabilnosti u prisutnosti β-laktamaza. It is the first clinically available member of a new group of β-lactam antibiotics that possess a carbapenem ring system. Imipenem shows an extremely broad spectrum of activity against gram-positive and gram-negative aerobic and anaerobic species, partly due to its great stability in the presence of β-lactamases.

Imipenem je prvi put objavljen u U.S. patentu br. 4 194 047 i dobiven je tehnikom liofilizacije. Pokazalo se da je produkt dobiven liofilizacijom uglavnom amorfan i navodi se da je termodinamički nestabilan. Postupak također uključuje početno pročišćavanje kromatografijom na koloni uz upotrebu hidrofobnih smola. Imipenem was first published in the U.S. patent no. 4 194 047 and was obtained by the lyophilization technique. The product obtained by lyophilization was shown to be mostly amorphous and is reported to be thermodynamically unstable. The process also includes initial purification by column chromatography using hydrophobic resins.

Termodinamički stabilan kristalni oblik monohidrata imipenema objavljen je u U.S. patentu br. 4 260 543, a dobiven je kristalizacijom liofiliziranog uzorka imipenema. Međutim, ovaj postupak ne zadovoljava na komercijalnoj razini i zahtijeva izolaciju produkta kromatografijom na koloni, liofilizaciju i kristalizaciju. Nadalje, produljeni postupak izolacije konačnog produkta dovodi do razgradnje imipenema, što utječe na čistoću produkta. A thermodynamically stable crystalline form of imipenem monohydrate was published in U.S. Pat. patent no. 4 260 543, and was obtained by crystallization of a lyophilized sample of imipenem. However, this procedure is not satisfactory on a commercial scale and requires isolation of the product by column chromatography, lyophilization and crystallization. Furthermore, the prolonged process of isolation of the final product leads to the degradation of imipenem, which affects the purity of the product.

U.S. patent br. 4 292 436 objavljuje kristalni imipenem pročišćavanjem sirovog produkta kromatografijom na koloni. Drugi postupak pripreme imipenema visokog stupnja kristalnosti postupkom smrzavanja i kristalizacije objavili su Connolly i sur. u J. Pharm. Sci., 85, 174(1996). Međutim, ti su postupci zamorni, nespretni i neprikladni za industrijsku primjenu. LOUSE. patent no. 4 292 436 discloses crystalline imipenem by purifying the crude product by column chromatography. Another procedure for the preparation of imipenem with a high degree of crystallinity by the freezing and crystallization process was published by Connolly et al. in J. Pharm. Sci., 85, 174 (1996). However, these procedures are tedious, clumsy and unsuitable for industrial applications.

Naša PCT prijava koja je u postupku, br. PCT/IB02/01718, daje postupak izolacije kristalnog imipenem monohidrata iz otopine koja sadrži imipenem bez upotrebe liofilizacije, sušenja smrzavanjem ili kromatografskih tehnika u bilo kojoj fazi. Our pending PCT application, no. PCT/IB02/01718, provides a procedure for isolating crystalline imipenem monohydrate from a solution containing imipenem without the use of lyophilization, freeze drying or chromatographic techniques at any stage.

Međutim, opaženo je da imipenem, dobiven postupcima koji ne uključuju kromatografiju na koloni, sadrži polimerne i obojene nečistoće. Polimerne nečistoće su popratni produkti nastali tijekom sinteze imipenema, a koji kristaliziraju zajedno s imipenemom. Te nečistoće ne pokazuju ultraljubičastu apsorpciju i zbog toga ih je teško detektirati. Iako se polimerne nečistoće ne odražavaju u kvalitativnom određivanju čistoće pomoću HPLC, kvantitativno određivanje (test) pokazuje da produkt sadrži oko 5-10% tih nečistoća. However, it has been observed that imipenem, obtained by procedures that do not involve column chromatography, contains polymeric and colored impurities. Polymeric impurities are by-products formed during the synthesis of imipenem, which crystallize together with imipenem. These impurities do not show ultraviolet absorption and are therefore difficult to detect. Although polymer impurities are not reflected in the qualitative determination of purity by HPLC, the quantitative determination (test) shows that the product contains about 5-10% of these impurities.

Obojene nečistoće su produkti razgradnje imipenema nastali tijekom proizvodnje ili pohrane, budući da je imipenemu svojstvena nestabilnost u otopini, kao i osjetljivost na toplinu i svjetlost. Te obojene nečistoće štetno utječu na pojavnost imipenema, koji se može javiti u obliku od blijedo žutog do smećkastog praha, umjesto željenog bijelog kristalnog praha. Colored impurities are degradation products of imipenem formed during production or storage, since imipenem is inherently unstable in solution, as well as sensitive to heat and light. These colored impurities adversely affect the appearance of imipenem, which may appear as a pale yellow to brownish powder, instead of the desired white crystalline powder.

Pročišćavanje imipenema otežano je zbog njegove nestabilne prirode. Kristalni imipenem ima relativno nisku topljivost u vodi pri sobnoj temperaturi. Postupak pročišćavanja zato zahtijeva otapanje imipenema u velikim volumenima vode. Kromatografsko pročišćavanje također zahtijeva eluciju s velikim volumenima vode. Postupak ponovnog prikupljanja pročišćenog produkta je neekonomičan, budući da zahtijeva koncentriranje vode pri niskoj temperaturi, dakle, neophodan je postupak liofilizacije, reverzne osmoze ili tehnike sušenja smrzavanjem. Purification of imipenem is difficult due to its unstable nature. Crystalline imipenem has a relatively low solubility in water at room temperature. The purification process therefore requires dissolving imipenem in large volumes of water. Chromatographic purification also requires elution with large volumes of water. The process of re-collecting the purified product is uneconomical, since it requires the concentration of water at a low temperature, therefore, the process of lyophilization, reverse osmosis or freeze-drying techniques is necessary.

Bit izuma The essence of invention

Predmet ovog izuma je jednostavan, praktičan i učinkovit postupak pripreme čistog kristalnog imipenem monohidrata iz sirovog imipenema koji sadrži nečistoće, uključujući polimerne i obojene nečistoće. The subject of this invention is a simple, practical and efficient process for the preparation of pure crystalline imipenem monohydrate from crude imipenem containing impurities, including polymeric and colored impurities.

Postupak ovog izuma ne koristi kapitalne intenzivne tehnike liofilizacije ili kristalizacije smrzavanjem, ni dugotrajne postupke pročišćavanja kromatografijom na koloni uz upotrebu skupih hidrofobnih smola. Ovaj izum tako upotpunjava potrebu za proizvodnjom imipenema prikladnom na komercijalnoj razini. The process of the present invention does not use capital-intensive lyophilization or freeze-crystallization techniques, nor time-consuming column chromatography purification procedures using expensive hydrophobic resins. This invention thus completes the need for the production of imipenem suitable on a commercial scale.

U skladu s time, ovaj izum daje postupak pripreme čistog kristalnog imipenem monohidrata formule I, Accordingly, this invention provides a process for the preparation of pure crystalline imipenem monohydrate of formula I,

[image] [image]

koji obuhvaća: which includes:

a) otapanje sirovog imipenema u vodi da bi se dobila otopina; a) dissolving crude imipenem in water to obtain a solution;

b) podvrgavanje nastale otopine tretmanu aktivnim ugljenom; i b) subjecting the resulting solution to treatment with activated carbon; and

c) dodavanje organskog otapala, da bi se istaložio imipenem monohidrat kao kristalni produkt. c) adding an organic solvent to precipitate imipenem monohydrate as a crystalline product.

Sirovi imipenem može se dobiti bilo kojim od postupaka opisanima u prethodnim radovima. Crude imipenem can be obtained by any of the procedures described in previous works.

U skladu s jednim aspektom ovog izuma, sirovi imipenem otopljen je u toploj vodi kojoj je dodano nešto baza i nastala otopina brzo je ohlađena da bi se spriječila bilo kakva razgradnja. Dodatak baze osiguraav stabilnost imipenema u otopini pri visokoj temperaturi održavanjem pH oko 7,5 do 8,5. Moguće je koristiti bilo koju bazu poznatu stručnjacima područja, a koja može dovesti pH vode u područje oko 7,5 do 8,5. Poželjno je koristiti natrijev karbonat. In accordance with one aspect of the present invention, crude imipenem is dissolved in warm water to which some base has been added and the resulting solution is rapidly cooled to prevent any decomposition. Addition of base ensures stability of imipenem in solution at high temperature by maintaining pH around 7.5 to 8.5. It is possible to use any base known to experts in the field, which can bring the pH of the water into the range of about 7.5 to 8.5. It is preferable to use sodium carbonate.

U skladu s izumom, voda je prethodno zagrijana na temperaturu oko 35 do 60°C. Oko 30 do 60 mL vode na 1 g sirovog imipenema dovoljno je da se postigne učinkovito pročišćavanje bez potrebe za koncentriranjem ili uklanjanjem vode da bi se izolirao produkt. According to the invention, the water is preheated to a temperature of about 35 to 60°C. About 30 to 60 mL of water per 1 g of crude imipenem is sufficient to achieve efficient purification without the need to concentrate or remove water to isolate the product.

Tretiranje ugljenom provodi se pri ambijentalnoj temperaturi i pri pH od oko 5 do 7 da bi se olakšala adsorpcija nečistoća. Po želji, tijekom tretiranja ugljenom dodaje se natrijev bisulfit da bi se dobili bolji rezultati. Polimerne nečistoće ostaju neotopljene u vodi i odfiltriraju se zajedno s ugljenom. Charcoal treatment is carried out at ambient temperature and at a pH of about 5 to 7 to facilitate the adsorption of impurities. If desired, sodium bisulfite is added during charcoal treatment to obtain better results. Polymeric impurities remain undissolved in water and are filtered out together with coal.

Nakon tretiranja ugljenom, bistroj, bezbojnoj otopini dodaje se organsko otapalo da bi se iskristalizirao čisti imipenem. Korak kristalizacije poželjno je provoditi pri temperaturama ispod 25°C, na primjer pri oko 0°C do oko 15°C. After treatment with charcoal, an organic solvent is added to the clear, colorless solution to crystallize pure imipenem. The crystallization step is preferably carried out at temperatures below 25°C, for example at about 0°C to about 15°C.

Primjeri organskih otapala uključuju niže alkohole, kao što su metanol, etanol, propanol i izopropanol; ketone, kao što su aceton i metil-etil-keton, ili njihove smjese. Examples of organic solvents include lower alcohols, such as methanol, ethanol, propanol and isopropanol; ketones, such as acetone and methyl ethyl ketone, or mixtures thereof.

Detaljan opis izuma Detailed description of the invention

U sljedećem dijelu opisana su poželjna ostvarenja putem primjera koji ilustriraju postupak ovog izuma. Međutim, ni na koji način nije im namjera ograničiti područje ovog izuma. In the following section, preferred embodiments are described by means of examples illustrating the process of this invention. However, they are not intended to limit the scope of the present invention in any way.

PRIPREMA KRISTALNOG IMIPENEM MONOHIDRATA PREPARATION OF CRYSTAL IMIPENEM MONOHYDRATE

Primjer 1 Example 1

Destilirana voda (4,0 L) koja sadrži natrijev bikarbonat (2,6 g) zagrijana je na 45 do 47°C u atmosferi dušika. Sirovi imipenem (100 g, test = 100%) dodan je u otopinu, miješano je 2 minute pri 45 do 47°C i zatim brzo ohlađeno na 5 do 10°C (u roku od 10 do 15 minuta). Prije hlađenja otopine na 5 do 10°C dodan je aktivni ugljen "Eno Anticromos" (30 g) pri 20 do 25°C. pH suspenzije podešen je na oko 6 dodatkom 3N klorovodične kiseline i miješano je 45 minuta pri 5 do 10°C pod dušikom. Ugljen je filtriran i ispran destiliranom vodom (500 mL). Filtrat je ohlađen ne 5 do 8°C i dodan je aceton (4,5 L) uz žestoko miješanje, pri čemu je održavana ista temperatura. Smjesa je dalje miješana 2-3 sata pri 5 do 10°C (taloženje kristalnog imipenem monohidrata započelo je 15 do 20 minuta nakon dodatka acetona). Potom je dodano još acetona (2,3 L) i suspenzija je miješana pri 0 do 5°C 3-4 sata. Kristalna krutina je filtrirana, isprana acetonom i osušena pod sniženim tlakom pri 40°C kroz 3-4 sata da bi se dobio bijeli kristalni imipenem monohidrat (73 g, test: 98,5%). Distilled water (4.0 L) containing sodium bicarbonate (2.6 g) was heated to 45 to 47°C under a nitrogen atmosphere. Crude imipenem (100 g, assay = 100%) was added to the solution, stirred for 2 minutes at 45 to 47°C and then rapidly cooled to 5 to 10°C (within 10 to 15 minutes). Before cooling the solution to 5 to 10°C, activated carbon "Eno Anticromos" (30 g) was added at 20 to 25°C. The pH of the suspension was adjusted to about 6 by the addition of 3N hydrochloric acid and stirred for 45 minutes at 5 to 10°C under nitrogen. The charcoal was filtered and washed with distilled water (500 mL). The filtrate was cooled to 5 to 8°C and acetone (4.5 L) was added with vigorous stirring, maintaining the same temperature. The mixture was further stirred for 2-3 hours at 5 to 10°C (precipitation of crystalline imipenem monohydrate started 15 to 20 minutes after addition of acetone). More acetone (2.3 L) was then added and the suspension was stirred at 0 to 5°C for 3-4 hours. The crystalline solid was filtered, washed with acetone and dried under reduced pressure at 40°C for 3-4 hours to give white crystalline imipenem monohydrate (73 g, assay: 98.5%).

Primjer 2 Example 2

Postupak iz Primjera 1 ponovljen je uz upotrebu sirovog kristalnog imipenema (100 g, test = 75%) da bi dao bijeli kristalni imipenem monohidrat (65 g, test: 98,3%). The procedure of Example 1 was repeated using crude crystalline imipenem (100 g, assay = 75%) to give white crystalline imipenem monohydrate (65 g, assay: 98.3%).

Primjer 3 Example 3

Destilirana voda (3,0 L) koja sadrži natrijev bikarbonat (2,6 g) zagrijana je na 48°C u atmosferi dušika. Sirovi imipenem (100 g, test = 92%) dodan je u otopinu i miješano je 2 minute pri 48°C, nakon čega je ohlađeno na 20 do 25°C u roku od 5 do 10 minuta. Pri istoj temperaturi otopini je dodan aktini ugljen "Eno Anticromos" (20 g). pH suspenzije podešen je na oko 6 dodatkom 3N klorovodične kiseline i miješano je 45 minuta pri 5 do 10°C pod dušikom. Ugljen je filtriran i ispran destiliranom vodom (500 mL). Filtratu je dodan aceton (3,5 L) pri 5 do 10°C. Smjesa je miješana 3 sata pri 5 do 10°C. Potom je dodano još acetona (5,0 L) i suspenzija je miješana pri 0 do 5°C 4 sata. Kristalna krutina je filtrirana, isprana acetonom i osušena pod sniženim tlakom pri 40°C da bi se dobio bijeli kristalni imipenem monohidrat (76 g, test: 99,0%). Distilled water (3.0 L) containing sodium bicarbonate (2.6 g) was heated to 48°C under a nitrogen atmosphere. Crude imipenem (100 g, assay = 92%) was added to the solution and stirred for 2 minutes at 48°C, after which it was cooled to 20 to 25°C within 5 to 10 minutes. Actinic carbon "Eno Anticromos" (20 g) was added to the solution at the same temperature. The pH of the suspension was adjusted to about 6 by the addition of 3N hydrochloric acid and stirred for 45 minutes at 5 to 10°C under nitrogen. The charcoal was filtered and washed with distilled water (500 mL). Acetone (3.5 L) was added to the filtrate at 5 to 10°C. The mixture was stirred for 3 hours at 5 to 10°C. More acetone (5.0 L) was then added and the suspension was stirred at 0 to 5°C for 4 hours. The crystalline solid was filtered, washed with acetone and dried under reduced pressure at 40°C to give white crystalline imipenem monohydrate (76 g, assay: 99.0%).

Primjer 4 Example 4

Postupak iz Primjera 3 ponovljen je uz upotrebu izopropanola umjesto acetona tijekom kristalizacije. Dobiven je kristalni imipenem monohidrat (71,5 g, test: 98,0%). The procedure of Example 3 was repeated using isopropanol instead of acetone during crystallization. Crystalline imipenem monohydrate was obtained (71.5 g, assay: 98.0%).

Iako je ovaj izum opisan u okvirima svojih specifičnih ostvarenja, stručnjacima područja bit će očigledne neke modifikacije i ekvivalentna rješenja, koja su uključena u područje ovog izuma. Although the present invention has been described within the scope of its specific embodiments, some modifications and equivalent solutions, which are included within the scope of the present invention, will be apparent to those skilled in the art.

Claims (15)

1. Postupak pripreme kristalnog imipenem monohidrata formule I [image] naznačen time da obuhvaća: a) otapanje sirovog imipenema u vodi da bi se dobila otopina; b) podvrgavanje nastale otopine tretmanu aktivnim ugljenom; i c) dodavanje organskog otapala, da bi se istaložio imipenem monohidrat kao kristalni produkt.1. Method of preparation of crystalline imipenem monohydrate formula I [image] characterized by including: a) dissolving crude imipenem in water to obtain a solution; b) subjecting the resulting solution to treatment with activated carbon; and c) adding an organic solvent to precipitate imipenem monohydrate as a crystalline product. 2. Postupak prema zahtjevu 1, naznačen time da se sirovi imipenem otapa u vodi koja je prethodno zagrijana na temperaturu od oko 35°C do oko 60°C.2. The method according to claim 1, characterized in that raw imipenem is dissolved in water that has been previously heated to a temperature of about 35°C to about 60°C. 3. Postupak prema zahtjevu 2, naznačen time da obuhvaća dodavanje baze u vodu da bi se održao pH vruće otopine od oko 7,5 do 8,5.3. The method according to claim 2, characterized in that it comprises adding a base to the water to maintain the pH of the hot solution from about 7.5 to 8.5. 4. Postupak prema zahtjevu 3, naznačen time da je baza natrijev bikarbonat.4. The method according to claim 3, characterized in that the base is sodium bicarbonate. 5. Postupak prema zahtjevu 1, naznačen time da je količina vode oko 30 do 60 mL po 1 g sirovog imipenema.5. The method according to claim 1, characterized in that the amount of water is about 30 to 60 mL per 1 g of raw imipenem. 6. Postupak prema zahtjevu 1, naznačen time da se tretiranje ugljenom odvija pri ambijentalnoj temperaturi.6. The method according to claim 1, characterized in that the coal treatment takes place at ambient temperature. 7. Postupak prema zahtjevu 1, naznačen time da se tretiranje ugljenom provodi pri pH od oko 5 do 7.7. The method according to claim 1, characterized in that the treatment with coal is carried out at a pH of about 5 to 7. 8. Postupak prema zahtjevu 1, naznačen time da se tretiranje ugljenom provodi u prisutnosti natrijevog bisulfita.8. The method according to claim 1, characterized in that the treatment with coal is carried out in the presence of sodium bisulfite. 9. Postupak prema zahtjevu 1, naznačen time da organsko otapalo sadrži niži alkohol, keton ili njihovu smjesu.9. The method according to claim 1, characterized in that the organic solvent contains a lower alcohol, ketone or their mixture. 10. Postupak prema zahtjevu 9, naznačen time da je niži alkohol izabran iz grupe koju čine metanol, etanol, propanol, izopropanol i njihove smjese.10. The method according to claim 9, characterized in that the lower alcohol is selected from the group consisting of methanol, ethanol, propanol, isopropanol and their mixtures. 11. Postupak prema zahtjevu 9, naznačen time da je keton aceton, metil-etil-keton ili njihova smjesa.11. The method according to claim 9, characterized in that the ketone is acetone, methyl-ethyl-ketone or their mixture. 12. Postupak prema zahtjevu 1, naznačen time da se kristalizacija provodi pri temperaturi ispod 25°C.12. The method according to claim 1, characterized in that the crystallization is carried out at a temperature below 25°C. 13. Postupak prema zahtjevu 12, naznačen time da je temperatura između oko 0°C i oko 15°C.13. The method according to claim 12, characterized in that the temperature is between about 0°C and about 15°C. 14. Spoj čija je struktura formule I [image] naznačen time da je pripremljen postupkom koji obuhvaća: a) otapanje sirovog imipenema u vodi da bi se dobila otopina; b) podvrgavanje nastale otopine tretmanu aktivnim ugljenom; i c) dodavanje organskog otapala, da bi se istaložio imipenem monohidrat kao kristalni produkt.14. A compound whose structure is formula I [image] characterized by the fact that it is prepared by a process that includes: a) dissolving crude imipenem in water to obtain a solution; b) subjecting the resulting solution to treatment with activated carbon; and c) adding an organic solvent to precipitate imipenem monohydrate as a crystalline product. 15. Spoj prema zahtjevu 14, naznačen time da mu je čistoća veća od 98%.15. Compound according to claim 14, characterized in that its purity is greater than 98%.
HR20040552A 2001-11-16 2004-06-16 Process for the preparation of crystalline imipenem HRP20040552A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1152DE2001 2001-11-16
PCT/IB2002/004804 WO2003042215A1 (en) 2001-11-16 2002-11-18 Process for the preparation of crystalline imipenem

Publications (1)

Publication Number Publication Date
HRP20040552A2 true HRP20040552A2 (en) 2004-10-31

Family

ID=11097136

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040552A HRP20040552A2 (en) 2001-11-16 2004-06-16 Process for the preparation of crystalline imipenem

Country Status (15)

Country Link
US (1) US7332600B2 (en)
EP (1) EP1448563A1 (en)
JP (1) JP2005509037A (en)
KR (1) KR20050044506A (en)
CN (1) CN1608066A (en)
AR (1) AR037551A1 (en)
BR (1) BR0214209A (en)
CA (1) CA2467427A1 (en)
EA (1) EA200400682A1 (en)
HR (1) HRP20040552A2 (en)
HU (1) HUP0402112A2 (en)
MX (1) MXPA04004604A (en)
PL (1) PL368984A1 (en)
WO (1) WO2003042215A1 (en)
ZA (1) ZA200403961B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA12608A (en) * 2001-05-18 2006-06-08 Ranbaxy Lab Ltd Process for the isolation of crystalline imiponem.
JP2005023081A (en) * 2003-06-11 2005-01-27 Api Corporation Crystal of arbutin and method for preparation of the same
US8615282B2 (en) 2004-07-13 2013-12-24 Dexcom, Inc. Analyte sensor
EP1991110B1 (en) 2006-03-09 2018-11-07 DexCom, Inc. Systems and methods for processing analyte sensor data
EP4218548A1 (en) 2006-03-09 2023-08-02 Dexcom, Inc. Systems and methods for processing analyte sensor data
CN101610999A (en) * 2006-12-15 2009-12-23 先灵公司 The hydrosulphite purification process of alpha-keto amide
US8621008B2 (en) 2007-04-26 2013-12-31 Mcafee, Inc. System, method and computer program product for performing an action based on an aspect of an electronic mail message thread
US8199965B1 (en) 2007-08-17 2012-06-12 Mcafee, Inc. System, method, and computer program product for preventing image-related data loss
US20130276061A1 (en) 2007-09-05 2013-10-17 Gopi Krishna Chebiyyam System, method, and computer program product for preventing access to data with respect to a data access attempt associated with a remote data sharing session
WO2009047604A1 (en) * 2007-10-08 2009-04-16 Orchid Chemicals & Pharmaceuticals Limited Process for the preparation of carbapenem antibiotic
US8893285B2 (en) 2008-03-14 2014-11-18 Mcafee, Inc. Securing data using integrated host-based data loss agent with encryption detection
US9077684B1 (en) 2008-08-06 2015-07-07 Mcafee, Inc. System, method, and computer program product for determining whether an electronic mail message is compliant with an etiquette policy
CN101891744B (en) * 2010-07-20 2012-06-13 深圳市海滨制药有限公司 Method for preparing Imipenem monohydrate crystals
CN101891745B (en) * 2010-07-20 2012-06-13 深圳市海滨制药有限公司 Method for preparing imipenem monohydrate crystal
WO2012081033A2 (en) * 2010-12-06 2012-06-21 Sequent Scientific Limited A process for preparation of imipenem
CN103524508B (en) * 2013-09-02 2016-03-30 上海龙翔生物医药开发有限公司 A kind of crystallization method of Imipenem monohydrate
CN113135916A (en) * 2020-01-20 2021-07-20 鲁南制药集团股份有限公司 Palladium removing method for imipenem preparation process
CN111747959B (en) * 2020-05-15 2022-02-11 深圳市海滨制药有限公司 Preparation method of imipenem raw material medicine
CN114671877B (en) * 2022-02-18 2023-05-16 珠海联邦制药股份有限公司 Refining method of imipenem

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE268240C (en)
JPS606957B2 (en) * 1973-04-10 1985-02-21 ブリストル マイヤ−ズ カンパニ− Method for producing antibiotic derivatives
US4194047A (en) 1975-11-21 1980-03-18 Merck & Co., Inc. Substituted N-methylene derivatives of thienamycin
US4260543A (en) 1978-07-03 1981-04-07 Merck & Co., Inc. Crystalline N-formimidoyl thienamycin
DK153486C (en) * 1978-07-03 1988-11-28 Merck & Co Inc ANALOGY PROCEDURE FOR THE PREPARATION OF CRYSTALLINIC N-FORMIMIDOYL-THIENAMYCINE MONOHYDRATE
US4292436A (en) 1980-06-25 1981-09-29 Merck & Co., Inc. Process for the preparation of N-protected N-formimidoyl 2-aminoethanethiol
US5061730A (en) * 1987-01-26 1991-10-29 Fujisawa Pharmaceutical Co., Ltd. Carboxylic acid derivatives
DD268240A1 (en) * 1987-12-05 1989-05-24 Univ Schiller Jena PROCESS FOR THE PRODUCTION OF HIGH-PURITY OF 2-HYDROXY-4-ALKOXYBENZOPHENONES SUITABLE FOR APPLICATION IN OPTICS OF POLYMERIC MATERIALS
US5321020A (en) * 1989-03-28 1994-06-14 Pfizer Inc. Antibacterial 2-carbapenem derivatives
CA2023144A1 (en) * 1989-08-21 1991-02-22 Frank P. Dininno 2-(quinoliniumalkyl and isoquinoliniumalkyl)-phenyl carbapenem antibacterial agents
JPH03256262A (en) 1990-03-07 1991-11-14 Nec Corp Magnetic disk device
US5240920A (en) * 1990-10-11 1993-08-31 Merck & Co., Inc. 2-(substituted-dibenzofuranyl and dibenzothienyl) carbapenem antibacterial agents
JPH06256262A (en) * 1993-03-08 1994-09-13 Sekiyu Sangyo Kasseika Center Purification of 2,6-naphthalene dicarboxylic acid dimethyl ester
US5621084A (en) * 1994-04-05 1997-04-15 Pfizer Inc. Process for removal of allyl group or allyloxycarbonyl group
WO1997009300A1 (en) * 1995-09-08 1997-03-13 Bracco International B.V. Process for the crystallization from water of (s)-n,n'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(2-hydroxy-1-oxopropyl)amino]-2,4,6-triiodo-1,3-benzendicarboxamide
JP2000506176A (en) * 1996-03-14 2000-05-23 ノボ ノルディスク アクティーゼルスカブ High yield of crystallized protein by using solid adsorbent
CN1109688C (en) * 1999-01-12 2003-05-28 中国药品生物制品检定所 Preparation and application of tazobactam semihydrate
AU3575700A (en) 1999-03-22 2000-10-09 Purac Biochem B.V. Method of industrial-scale purification of lactic acid
GB9925215D0 (en) * 1999-10-26 1999-12-22 Cerestar Holding Bv Process for the manufacture of citric acid
WO2001072750A1 (en) * 2000-03-31 2001-10-04 Shionogi & Co., Ltd. Novel crystal form of pyrrolidylthiocarbapenem derivative
IN191798B (en) * 2000-11-03 2004-01-03 Ranbaxy Lab Ltd
AR035728A1 (en) * 2001-01-16 2004-07-07 Merck & Co Inc PERFECTED PROCESS FOR CARBAPENEM SYNTHESIS
OA12608A (en) * 2001-05-18 2006-06-08 Ranbaxy Lab Ltd Process for the isolation of crystalline imiponem.
US7022841B2 (en) * 2001-09-26 2006-04-04 Merck & Co. Inc. Process for making carbapenem compounds
US7145002B2 (en) * 2001-09-26 2006-12-05 Merck & Co. Inc. Crystalline forms of carbapenem antibiotics and methods of preparation

Also Published As

Publication number Publication date
PL368984A1 (en) 2005-04-04
BR0214209A (en) 2004-10-26
KR20050044506A (en) 2005-05-12
WO2003042215A1 (en) 2003-05-22
EP1448563A1 (en) 2004-08-25
US20050004359A1 (en) 2005-01-06
US7332600B2 (en) 2008-02-19
MXPA04004604A (en) 2004-09-10
CA2467427A1 (en) 2003-05-22
JP2005509037A (en) 2005-04-07
CN1608066A (en) 2005-04-20
HUP0402112A2 (en) 2005-02-28
EA200400682A1 (en) 2004-10-28
AR037551A1 (en) 2004-11-17
ZA200403961B (en) 2005-09-19

Similar Documents

Publication Publication Date Title
HRP20040552A2 (en) Process for the preparation of crystalline imipenem
EP0342990B1 (en) Process for preparing erythromycin A oxime or a salt therof
CS215142B2 (en) Method of making the solid solvates of the syn-+l2-+l-amino-4-thiazolyl+p-2-methoxyimino+p acetymido-3-acetoxymethyl-3-cefem-4-carboxyl acid with cycling ethers
KR20100038081A (en) Process for preparing amorphous refaximin and the amorphous refaximin thus obtained
US8293924B2 (en) Process for the preparation of carbapenem antibiotic
CN101891742A (en) Preparation method of meropenem trihydrate crystal
EA006442B1 (en) Process for the preparation of crystalline n-formimidoyl thienamycin monohydrate (imipenem monohydrate)
CN105859747B (en) A kind of preparation method of cefepime Hydrochloride suitable for industrialized production
JPH04500819A (en) Improvements in or related to organic compounds
US7241885B2 (en) Process for the isolation of crystalline imipenem
AU2002347451A1 (en) Process for the preparation of crystalline imipenem
MX2007010431A (en) Process of purifying tadalafil.
US5387703A (en) Process and intermediate for the purification of oxytetracycline
CN106565784B (en) The purification process of Ceftaroline Fosamil disodium salt
CA2575912C (en) Process for the preparation of optically pure indoline-2-carboxylic acid
CN112480146B (en) Cefuroxime acid mixed solvate, crystal form and preparation method
CA2124382A1 (en) 14.alpha.-hydroxy-4-androstene-3,6,17-trione hydrate crystal and process for producing same
AU728627B2 (en) Cephalosporin crystals and process for their preparation
WO2004037832A1 (en) An improved process for the preparation of cefixime
WO2012081033A2 (en) A process for preparation of imipenem
EP0497125B1 (en) New process for preparing 2'-(diethylamino)rifamycin P (P/DEA)
KR840000482B1 (en) Process for preparing cephadroxy formamide
IL29529A (en) Orally active 7-(4'-(aminoalkyl)phenyl)acetamido cephalosporanic acid derivatives

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20051025

Year of fee payment: 4

OBST Application withdrawn